India’s opportunity to build preventive healthcare economy
The country’s strength lies not just in technology availability but in adoption behaviour
The country’s strength lies not just in technology availability but in adoption behaviour
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
The company reported free cash flow of Rs. 2,590 Mn for FY26
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Access to genomic testing, not therapy cost, is the biggest challenge
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Subscribe To Our Newsletter & Stay Updated